These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

376 related items for PubMed ID: 29244650

  • 21. Pharmacotherapy for obesity in individuals with type 2 diabetes.
    Chukir T, Shukla AP, Saunders KH, Aronne LJ.
    Expert Opin Pharmacother; 2018 Feb; 19(3):223-231. PubMed ID: 29376439
    [Abstract] [Full Text] [Related]

  • 22. Melatonin, Liraglutide, and Naltrexone/Bupropion for the Treatment of Obesity and Medication-Related Weight Gain.
    Howland RH.
    J Psychosoc Nurs Ment Health Serv; 2015 Jun; 53(6):19-22. PubMed ID: 26091546
    [Abstract] [Full Text] [Related]

  • 23. Pharmacotherapy of Obesity: Clinical Trials to Clinical Practice.
    Gadde KM, Pritham Raj Y.
    Curr Diab Rep; 2017 May; 17(5):34. PubMed ID: 28378293
    [Abstract] [Full Text] [Related]

  • 24. New antiobesity agents: lorcaserin (Belviq) and phentermine/topiramate ER (Qsymia).
    Shyh G, Cheng-Lai A.
    Cardiol Rev; 2014 May; 22(1):43-50. PubMed ID: 24304809
    [Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27. Review of pharmacotherapy options for the management of obesity.
    Bragg R, Crannage E.
    J Am Assoc Nurse Pract; 2016 Feb; 28(2):107-15. PubMed ID: 26119641
    [Abstract] [Full Text] [Related]

  • 28. [Cutting-edge of medicine; the prospects of novel anti-obesity drugs].
    Ueno H, Nakazato M.
    Nihon Naika Gakkai Zasshi; 2014 Mar 10; 103(3):753-9. PubMed ID: 24796150
    [No Abstract] [Full Text] [Related]

  • 29. Efficacy comparison of medications approved for chronic weight management.
    Kumar RB, Aronne LJ.
    Obesity (Silver Spring); 2015 Apr 10; 23 Suppl 1():S4-7. PubMed ID: 25900871
    [Abstract] [Full Text] [Related]

  • 30. New-generation anti-obesity drugs: naltrexone/bupropion and liraglutide. An update for endocrinologists and nutritionists.
    Barrea L, Pugliese G, Muscogiuri G, Laudisio D, Colao A, Savastano S.
    Minerva Endocrinol; 2020 Jun 10; 45(2):127-137. PubMed ID: 32643356
    [Abstract] [Full Text] [Related]

  • 31. Current pharmacotherapies for obesity: A practical perspective.
    Golden A.
    J Am Assoc Nurse Pract; 2017 Oct 10; 29(S1):S43-S52. PubMed ID: 29024552
    [Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. Safety assessment of combination therapies in the treatment of obesity: focus on naltrexone/bupropion extended release and phentermine-topiramate extended release.
    Halpern B, Mancini MC.
    Expert Opin Drug Saf; 2017 Jan 10; 16(1):27-39. PubMed ID: 27732121
    [Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35. Phentermine: an appetite-suppressant amphetamine classified as a narcotic in France. Is a combination with topiramate on the horizon?
    Prescrire Int; 2012 Sep 10; 21(130):209. PubMed ID: 23016252
    [Abstract] [Full Text] [Related]

  • 36. Weight Loss Pharmacotherapy: Current and Future Therapies.
    Jordan G, Young S, Alemán JO.
    Gastrointest Endosc Clin N Am; 2024 Oct 10; 34(4):591-608. PubMed ID: 39277293
    [Abstract] [Full Text] [Related]

  • 37. Orlistat for obesity.
    Med Lett Drugs Ther; 1999 Jun 18; 41(1055):55-6. PubMed ID: 10436767
    [No Abstract] [Full Text] [Related]

  • 38. Pharmacological Treatment for Obesity in Adults: An Umbrella Review.
    Khalil H, Ellwood L, Lord H, Fernandez R.
    Ann Pharmacother; 2020 Jul 18; 54(7):691-705. PubMed ID: 31958967
    [Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 19.